Your product here
The featured placement at the top of your category: your product, a one-line pitch, and links to your demo and booking page.
DotAEye tracks the AI products ophthalmologists and optometrists can actually buy: screening, home monitoring, imaging analysis, and practice operations. Each listing shows its regulatory status, what it reads, and who it's built for.
A one-day working meeting where practicing ophthalmologists and optometrists sit down with the founders, engineers and investors building AI for eyecare.
Connects industry teams with the right eye care providers for advisory boards, research, education and speaking, based on the work they actually do.
26 tools
The featured placement at the top of your category: your product, a one-line pitch, and links to your demo and booking page.
Ambient scribe in Compulink's ophthalmology suite that drafts progress notes and ICD-10 codes during consultations; the suite also includes the CASIE support assistant. Shown at AAO 2024.
Autonomous diabetic retinopathy screening software that runs on images from a handheld or tabletop camera and returns a referable/not-referable result at the visit.
Cloud, vendor-neutral OCT image management and analysis platform that detects many retinal pathologies and biomarkers; the vendor labels the AI analysis research-use-only.
FDA clearance covers image management; the vendor labels the AI analysis research-use-only.
Cloud eyecare EHR and practice platform with an AI scribe, AI Smart Scan intake, and an AI office copilot for scheduling and call logs. AOAExcel invested in it.
Reads a standard retinal photo to estimate cardiovascular disease risk during a routine eye exam. Toku also sells BioAge and has MyKidneyAI in development.
US: FDA Breakthrough designation only, not clearance.
Ophthalmology-first AI assistant that streams discrete data such as visual acuity and IOP directly into EHR chart fields. Launched Jan 27, 2026.
Cloud-based autonomous AI that grades retinal photographs for diabetic retinopathy, including a separate vision-threatening call. The vendor also markets detection of AMD and glaucomatous optic nerve signs under its EU certification.
FDA clearance covers diabetic retinopathy only.
A home device using hyperacuity (preferential-hyperacuity) testing to detect early conversion from dry to wet AMD, with results reviewed remotely by the vendor and clinician. FDA classifies it as an automatic perimeter; the vendor describes AI-enabled analysis, but the FDA clearance itself is not an AI clearance.
FDA clears it as an automatic perimeter, not as an AI device.
Free online IOL power calculator that uses radial basis function pattern recognition (an AI method) to predict postoperative refraction from biometry. Also built into Haag-Streit Lenstar/EyeSuite software.
AI software that screens color fundus images for more-than-mild diabetic retinopathy in adults with diabetes. FDA cleared in mid-2026; the company's AMD and glaucoma modules are not yet FDA cleared.
Online IOL power formula described in the literature as combining theoretical optics with regression and AI components. Also available through multi-formula platforms such as the ESCRS IOL calculator.
Autonomous software that reads retinal photographs and reports whether more-than-mild diabetic retinopathy is present, without a clinician interpreting the image. Originally the first FDA-authorized autonomous AI diagnostic.
Suite built into the MaximEyes EHR with a front-desk virtual assistant, billing assistant, voice scribe for SOAP notes, and document-recognition intake. Debuted Sept 18, 2025.
Offline deep-learning algorithm that runs on a smartphone-based fundus camera to flag referable diabetic retinopathy within seconds.
AI-assisted add-on that quantifies meibography images from the Keratograph 5M and grades gland dropout and morphology on the Arita scale to support dry eye and MGD assessment. Announced May 2026.
Ambient AI scribe built into ModMed's EMA ophthalmology EHR that listens to the visit and proposes structured notes, orders and prescriptions for clinician review.
Ambient documentation tool tuned for ophthalmology and optometry terminology that drafts eye-exam notes into the NextGen Enterprise EHR after provider review. Eye care version available since October 2024.
Deep-learning software that analyzes fundus photographs for signs of diabetic retinopathy and age-related macular degeneration and grades severity. Sold in Europe; no FDA status found.
Vendor-neutral platform that collects OCT and fundus data from multiple devices and layers on AI analysis; its OCT Atlas algorithm covers AMD, GA, DR, DME and glaucoma.
FDA clearance covers image management; AI outputs not confirmed within cleared indications.
AI eye-screening software that flags signs of pathology on fundus images and OCT scans and measures cup/disc ratio and disc area, with explainable overlays.
AI that quantifies intraretinal fluid, subretinal fluid and PED on OCT for wet AMD, and measures geographic atrophy, to support treatment decisions.
Retinal image analysis that detects microaneurysms and tracks their appearance and disappearance over time by aligning serial images, used for diabetic retinopathy screening programs.
Voice-driven scribe inside the optometry EHR that transcribes the exam conversation and fills structured record fields. Launched April 28, 2026.
A patient-operated OCT device that scans the retina at home, with automated analysis of fluid biomarkers sent to the physician to monitor wet AMD between office visits.
AI receptionist for eyecare practices that books exams, handles contact lens and Rx refill requests, fills cancellations from waitlists, triages urgent calls and sends balance reminders.
A data-driven IOL power algorithm using AI and paraxial ray tracing that does not need lens constants, trained on large real-world datasets. Offered inside ZEISS surgery-planning software.